Preventive medicine runs on numbers, and those numbers are often more complicated than the recommendations built on them. The gap between a statistic and what it means for any given person is where most health miscalibration actually lives.

The Synthesis: Multi-cancer early detection (MCED) tests are blood-based assays designed to detect cancer signals across dozens of organ types from a single blood draw. They are commercially available in several markets and increasingly marketed directly to consumers. Initial results from the PATHFINDER II study, presented at the European Society for Medical Oncology, and involving more than 23,000 participants, found that a cancer signal was detected in just under 1 percent of participants. Among those with a positive result, 61.6 percent had confirmed cancer, and unnecessary invasive procedures occurred in only 0.6 percent of cases. Overall sensitivity across all cancer types was approximately 40 percent, meaning the test misses roughly six in ten cancers present in the screened population. Standard screening continues to outperform these tests for cancers with established detection protocols, including breast and colorectal malignancies.

The Calibration: Currently, the value of MCED tests is highest for cancers with no existing screening alternative, which accounted for roughly three quarters of MCED-detected cancers in the PATHFINDER II study. MCED tests remain under FDA review. Based on current evidence, these tests are not ready to serve as a universal annual screening tool for adults at average risk.

The Synthesis: The case for prescribing statins to adults at low baseline cardiovascular risk has narrowed further with the 2026 American College of Cardiology/American Heart Association multisociety dyslipidemia guideline, published in Circulation. This replaces the Pooled Cohort Equations with the newer PREVENT-ASCVD equations for estimating cardiovascular risk. PREVENT estimates 10-year cardiovascular risk about 40 to 50 percent lower than the older tool for the same patient profile, and modeling analyses suggest the change would reduce the number of adults meeting thresholds for statin consideration by 14 to 17 million in the US alone. The change reflects a broader evidence base showing that absolute benefit is modest for adults at lower baseline risk. A systematic review prepared for the US Preventive Services Task Force found that among adults with a 10-year cardiovascular disease risk of 7.5 to 10 percent, treating 100 adults for five years prevents about one major cardiovascular event, reducing absolute risk from roughly 9 in 100 to 8 in 100. Comparable reviews in Canada and the United Kingdom have reached similar conclusions.

The Calibration: The benefit of statins is frequently overestimated for individuals whose only elevated risk factor is a moderately raised low-density lipoprotein (LDL) cholesterol level, in the absence of concurrent hypertension, smoking, or diabetes. The 2026 guideline formalizes what the evidence has supported for several years: that cholesterol levels in isolation are an unreliable trigger for long-term therapy, and that absolute risk rather than any single biomarker should anchor the treatment decision. Lifestyle modification and management of coexisting metabolic risk factors remain the higher-yield intervention for this population.

The Synthesis: Public health messaging on exercise has historically centered on aerobic activity. Resistance training receives substantially less attention in lay communication, despite a consistent evidence base. A systematic review and meta-analysis in the British Journal of Sports Medicine analyzed 16 studies and found that muscle-strengthening activity was associated with a 10-17% lower risk of all-cause mortality, cardiovascular disease, total cancer, diabetes and lung cancer. The association held independently of aerobic activity levels.

The Calibration: The evidence base is predominantly observational and cannot establish causation with certainty. That said, the finding is consistent across studies, shows meaningful risk reduction at relatively modest volumes of activity, and is biologically plausible: muscle mass maintenance supports metabolic health and physical resilience across aging. World Health Organization guidelines include resistance training recommendations, but public awareness lags well behind awareness of cardiovascular exercise guidance. The systematic underrepresentation of resistance training in health communication represents a correctable miscalibration.

Health coverage is dense with percentage-based risk claims such as: a drug reduces risk by 35%, or a food habit increases it by 40%. Most of these figures describe relative risk: they compare the risk between two groups rather than showing how common the outcome actually is. On their own they appear informative but they are often misleading. The problem is not that the numbers are wrong. It is that they omit the one piece of information that determines whether the finding is actually meaningful: the baseline risk.

Nearly all relative risk statistics express the ratio of risk between two groups without stating what the underlying risk actually is. A 50% reduction sounds transformative. If the baseline risk is 2 in 100, it becomes 1 in 100. If it is 0.2 in 100, it becomes 0.1 in 100. These are entirely different situations, and the relative figure communicates neither. Because larger percentages feel like larger effects, the framing reliably overstates the personal relevance of population-level findings.

This confusion is not always deliberate. Relative risk figures are mathematically useful for comparing populations with different baseline rates, and researchers legitimately use them for that purpose. The problem arises in translation: press releases and media coverage almost never supply the baseline, and readers have no default instinct to ask for it. This pattern has been documented by researchers studying medical risk communication. Modest findings routinely land as alarming, and the same underlying data can produce wildly different impressions depending only on which number a headline chooses.

The practical move is simple: when a percentage appears without its baseline, withhold the number's significance entirely. It describes a ratio, not a magnitude, and a ratio without its denominator carries no usable information. The question to hold is: compared to what starting point? A 30% reduction in a condition affecting 1 in 2 people is a very different proposition from a 30% reduction in a condition affecting 1 in 1,000. The percentage is the same. The relevance is not.

The Claim: The presence of microplastics in carotid artery plaque causes a dramatic increase in the risk of heart attack, stroke, or death, a characterization that accompanied widespread media coverage of an observational study published in the New England Journal of Medicine.

The Distortion: The study enrolled patients already undergoing surgery for asymptomatic carotid artery disease, a group with substantially elevated baseline cardiovascular risk. Published letters in the same journal subsequently raised contamination concerns, noting that the surgical environment contains the same plastic compounds detected in the plaque specimens and that no anti-contamination procedures were in place. The study design is observational and cannot establish causation, and the absolute risk differential in the general adult population cannot be inferred from data collected exclusively in a high-risk surgical cohort.

The Calibration: The accumulation of synthetic polymers in human tissue is a legitimate area for long-term environmental health research. On current evidence, it does not warrant changes in individual clinical management or acute concern in otherwise healthy adults.

The Claim: Magnesium supplements reliably improve sleep quality and are widely recommended as a natural remedy for difficulty falling or staying asleep.

The Distortion: The trial evidence supporting this is small in scale, short in duration, and heterogeneous, with many studies involving older adults, people with insomnia, or individuals likely to have low magnesium levels. In people with normal magnesium levels, who make up most adults in high-income countries, evidence for a meaningful sleep benefit remains limited and inconsistent. A large randomized, placebo-controlled trial published in 2025 enrolled healthy adults with poor sleep quality and found that magnesium bisglycinate supplementation modestly improved insomnia severity. However, the overall evidence base remains too limited and heterogeneous to support reliable general use.

The Calibration: Magnesium supplementation may have a role in correcting clinical deficiency or in selected populations, but it has not been established as an effective sleep intervention for the general population.

Stay calibrated.

If The Calibration brought you a clearer perspective today, forward it to someone who values the same.

Received this from a friend or colleague? Subscribe here to get it directly.

Blood-Based Tests For Multicancer Early Detection (PATHFINDER): A Prospective Cohort Study. The Lancet, 2023.

Safety And Performance Of A Multi-Cancer Early Detection (MCED) Test In An Intended-Use Population: Initial Results From The Registrational Pathfinder II Study. Annals of Oncology, 2025.

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2026.

The 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia: A More Precise - But More Complicated - Framework for Atherosclerotic Cardiovascular Disease Prevention and Treatment. Circulation, 2026.

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Journal of the American Medical Association, 2022.

Muscle-Strengthening Activities Are Associated With Lower Risk And Mortality In Major Non-Communicable Diseases: A Systematic Review And Meta-Analysis Of Cohort Studies. British Journal of Sports Medicine, 2022.

Simple Tools for Understanding Risks: From Innumeracy to Insight. British Medical Journal, 2003.

Microplastics and Nanoplastics in Atheromas and Cardiovascular Events. The New England Journal of Medicine, 2024.

Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nature and Science of Sleep, 2025.

The Calibration is an editorially curated health briefing. Content is drawn from published research and credible sources for informational purposes only. It does not constitute medical advice, clinical guidance, diagnosis, or treatment, and is not a substitute for consultation with a qualified healthcare professional. Nothing in this briefing should be used to make health or treatment decisions or to delay seeking professional medical advice.

Sponsored content, when present, will always be clearly identified.